Site Search

1. 161.
   AMP/assets/File/education/case-studies/1019_26-28_AMPcase_LowRes.pdf?pass=31

   B C:100% T:0% E S A C T G A T C C A T 5 10 75 50 250 A C: 32% T: 68% E S A C T G A T C C A T 5 10 50 250 C C: 0% T: 100% E S A C T G A T C C A T 5 10 20 -2 -4 -6 D n.a. Fig. 4 (A–D). PCR products purified by PyroMark Q96 Vacuum Workstation (Qiagen, GmbH, Germany) were subject to pyrosequencing on PyroMark Q96 ID instrument (Qiagen). Analysis was performed

   https://www.amp.org/AMP/assets/File/education/case-studies/1019_26-28_AMPcase_Lo...
2. 162.
   AMP/assets/File/position-statements/2015/AMPlettertoEConCuresAct-FINAL.pdf?pass=55

   cancer occur less than 1% of the time. Specifically, while lung adenocarcinomas have a rather high incidence, ... Test Evaluation Process (CTEP): http://www.palmettogba.com/palmetto/MolDX.nsf/DocsCat/MolDx%20Website~MolDx~Browse%20By%20Topic~General~8PKRZF3404?open&navmenu=Browse%5eBy%5eTopic|||| AMP’s comments submitted to the docket on FDA’s LDT draft

   https://www.amp.org/AMP/assets/File/position-statements/2015/AMPlettertoEConCure...
3. 163.
   AMP/assets/File/clinical-practice/0725_30-32_AMPcase-Fisch_repirnt-hires.pdf?pass=...

   Leu265Pro 17.80% CXCR4 c.1016dupG, p.Gly340Trpfs*8 21.30% BARD1 c.1518T>G, p.His506Gln 18.60% H3F3A c.104G>T, p.Gly35Val1 15.10% ERBB4 c.1909C>A, p.Pro637Thr 13.90% Table 1. Variants identified on next-generation sequencing 1 Equivalent to p.Gly34Val, depending on which of two adjacent methionines is included in the codon numbering. 2|CAP

   https://www.amp.org/AMP/assets/File/clinical-practice/0725_30-32_AMPcase-Fisch_r...
4. 164.
   AMP/assets/File/clinical-practice/20170321-Jenningsetal2017_AMPresourceTemplate3...

   Targeted region meeting minimum quality criteria [%] Known variants in the region# Known variants detected ( ... 2 3 … 60 Mean SE of the mean 95% lower CI 95% lower TI Legend: During validation, for each sample the ... 2017. The mean, standard error of the mean, 95% lower confidence interval and 95% tolerance interval should be calculated by variant type. #These

   https://www.amp.org/AMP/assets/File/clinical-practice/20170321-Jenningsetal2017_...
5. 165.
   RNA-based testing uncovers great diversity in lung cancer mutations - Association ...

   The mutations leading to MET exon 14 skipping occur in 3% to 4% of non–small cell lung cancer (NSCLC) patients. ... based testing, with an overall success rate of 98%, indicating that reliable detection of MET exon 14 alterations ... between the first EQA round in 2022 (37.5% success rate) and the second in 2024 (63% success rate), this shows that detection of MET

   https://www.amp.org/about/newsroom/amp-blog-content/rna-based-testing-uncovers-g...
6. 166.
   Clinical Practice Guidelines and Comments

   This year, there were 26 eligible YIA applicants, which represents a 30% increase from 2010. As ... responses, with more than 85% from individuals who were actively ... principal findings were: • >70% were performing clinical diagnostic PGX ... future PGX testing. • 80% of respondents supported addressing ... number of respondents (68%) indicated testing for somatic

   https://www.amp.org/AMP/assets/File/committees/reports/CompiledReports2011.pdf?p...
7. 167.
   AMP/assets/File/awards/technologist/TechAward_WinningAbstracts.pdf?pass=68

   Quantification was expressed as % mutant. Results: The T315I mutation ... T315I-positive case with 100% mutant allele was serially diluted ... indicated a sensitivity of approximately 5%. Conclusions: We describe a quantitative, sensitive ... influenza A detection, achieved 99% sensitivity (one potential false negative) and 100% specificity. Oseltamivir-resistant strains

   https://www.amp.org/AMP/assets/File/awards/technologist/TechAward_WinningAbstrac...
8. 168.
   AMP/assets/File/position-statements/2014/AMPComments2015PhysicianFeeSchedule2014...

   Process (CTEP),” see http://www.palmettogba.com/palmetto/MolDX.nsf/DocsCat/MolDx%20Website~MolDx~Browse%20By%20Topic~General~8PKRZF3404?open&navmenu=Browse%5eBy%5eTopic||||) which provides greater clarity about their process but imposes an evidence bar that very few laboratories can meet. Its high evidentiary bar –based on standards for new prescription

   https://www.amp.org/AMP/assets/File/position-statements/2014/AMPComments2015Phys...
9. 169.
   FileNewTemplate

   Comprehensive PIK3CAtesting would increase response rate in the first-line setting by only 1%.•The prognostic impact of ... and metastases Genes TestedConcordance Rate (%)KRAS (n=117)91.0KRAS, NRAS ... that a benchmark of 90% of specimens should be sent ... with at least 5% mutant allele frequency, taking ... that a benchmark of 90% of reports available within 10

   https://www.amp.org/AMP/assets/file/clinical-practice/CRCMMTeachingppt_FINAL.pdf...
10. 170.
    AMP/assets/File/annualreports/AMP_2022_Annual_Report.pdf?pass=36

    Membership increased a satisfactory 4.7%, Associate Membership grew by an incredible 53.6% (and has grown by 117% since the introduction of free Associate Membership for trainees ... To learn more, visit educate.amp.org. Had 84% of 2022 MGP Diplomates use at least one of ... 2022, resulting in over 360,000 page views. 61% of AMPEDTM users are non-members 12 ANNUAL REPORT

    https://www.amp.org/AMP/assets/File/annualreports/AMP_2022_Annual_Report.pdf?pas...